Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

Chemcon Speciality Chemicals - IPO Review - ICICI Securities

Posted On: 2020-09-21 07:38:53


Chemcon Speciality Chemicals is a manufacturer of specialised chemicals, such as HMDS (hexamethyldisilazane) and CMIC (chloromethyl isopropyl carbonate), which are predominantly used in the pharmaceuticals industry. Further the company also manufacturers inorganic bromides namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry. It is the only manufacturer of HMDS in India and were the third largest manufacturer of HMDS worldwide in terms of production.

Upcoming Capex likely to boost pharma chemical revenue & OPM

The company has recently increased its capacity for HMDS from 1800 MT to 4800 MT (~600 MT high purity HMDS and rest normal HMDS). Further, the company also plans to utilise around Rs. 41 crore from the IPO proceeds for the expansion of CMIC, which should likely to expand company's processing capacity by ~60%. We believe the company enjoys higher realisations in its pharma chemical business as compared to oil field chemicals and thus, it is evident that these two business verticals will likely to grow at decent pace in the coming few years on the back of import substitution. This should provide better OPM visibility for medium term.

Key risk & concerns

- Pricing pressure from China to impact performance ahead
- High working capital remains a key risk for balance sheet
- Priced at P/E of 25.5x (post issue) FY20 on upper band

Since CMIS goes into Tenofovir and with expectations of better growth outlook from the aforementioned drug over the period, one can expect better growth outlook for the company. Further, increase in the capacity for both HMDS and CMIS by Chemcon, one should expect pharma chemical business revenue to be more tilted to the group revenue ahead and thereby the operational performance. At the higher end of the price band of Rs. 340, the stock is available at a P/E of ~25.5x (on post issue basis) and EV/EBITDA of ~15.8x (post issue). We have a SUBSCRIBE rating on the issue.

For details, click on the link below: https://www.icicidirect.com/mailimages/IDirect_ChemconSpeciality_IPOReview.pdf


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities

REDUCE on RBL Bank - Some positives, but key concerns remain - HDFC Securities

Maintain REDUCE on Marico - Saffola shines with PCNO recovery, muted margin - HDFC Securities

Maintain ADD on Dr. Reddy's Labs - Good quarter, lower SG&A cost is encouraging - HDFC Securities

Piramal Enterprises - Acquisition of stake from JV partner - Angel Broking

Maintain BUY on Axis Bank - Provision buffers strengthened (further) - HDFC Securities

AU Small Finance Bank - Q2FY21 Result - Angel Broking

L&T - Q2FY21 - Angel Broking

RBL Bank - Q2FY21 Result - Angel Broking

Axis Bank - Q2FY21 Result - Angel Broking

Marico Ltd - Q2FY21 Result Update - YES Securities

Titan Company Ltd - Q2FY21 Result Update - YES Securities

Axis Bank Limited - Q2FY21 Result Update - YES Securities

RBL Bank Limited - Q2FY21 Result Update - YES Securities

Multi Commodity Exchange of India - Operating leverage aids strong EBITDA performance - ICICI Securities

Titan Company - Faster-than-expected recovery - ICICI Securities

Marico - Strong performance across portfolio - ICICI Securities

Heritage Foods - Lower procurement prices leading to highest EBITDA margin in past decade - ICICI Securities

Axis Bank - Strong core again utilised to create provisioning buffer - ICICI Securities

Supreme Industries - Beat on all counts - ICICI Securities

GSK Pharmaceuticals - Recovery from COVID-19 impact - ICICI Securities

Hero MotoCorp - Solid demand recovery expectations priced in - ICICI Securities

Cement - Demand / prices improve further in Oct'20 - ICICI Securities

CEAT - Replacement demand drives outperformance - ICICI Securities

Dr. Reddy's Laboratories - Outperformance continues - ICICI Securities

ICICI Prudential Life Insurance - VNB trajectory in-line despite YoY dip in protection in Q2 - ICICI Securities

Bharti Airtel - Q2FY21 Result Update - ICICI Securities

Marico - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro - Q2FY21 First Cut - ICICI Securities

Sanofi India - Q3CY20 Company Update - ICICI Securities

Adani Ports and SEZ - Quant Pick - ICICI Securities

Nippon Life India AMC - Q2FY21 Result Update - ICICI Securities

Tata Motors - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Mahanagar Gas - Positional Future - ICICI Securities

Supreme Industries - Q2FY21 First Cut - ICICI Securities

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Marico Ltd - Q2FY21 First Cut - ICICI Securities

Apcotex Industries - Q2FY21 First Cut - ICICI Securities

V-Guard Industries - Q2FY21 First Cut - ICICI Securities

Titan Company - Q2FY21 First Cut - ICICI Securities

Navin Fluorine - Q2FY21 First Cut - ICICI Securities

PI Industries - Q2FY21 First Cut - ICICI Securities

L&T - Q2FY21 Earnings First Cut: Beat on EBITDA margins - YES Securities

Bharti Airtel - Q2FY21 result - Angel Broking

Dr.Reddy's Lab - Q2FY21 - Angel Broking

BUY on Mahindra & Mahindra Financial Services - Remains an inexpensive rural play - HDFC Securities

Radico Khaitan - Q2FY21 - Angel Broking

Maintain BUY on CDSL - Firing on all cylinders - HDFC Securities

REDUCE on Nippon Life India Asset Management - Market share stabilising - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019